Summit Therapeutics’ ivonescimab, a PD1-VEGF antibody, has failed to demonstrate a survival benefit for patients with lung cancer. Despite showing promise in delaying disease progression in U.S. and Western countries, the results are inconsistent with those seen in Chinese patients enrolled in earlier trials. The drug’s performance has raised concerns about its potential as a blockbuster treatment.
Ivonescimab’s shares plummeted 30% following the announcement, putting pressure on Summit to reassess its regulatory filing plans for the drug. With the FDA potentially holding up approval, the future of ivonescimab looks uncertain.
Source: https://www.statnews.com/2025/05/30/summit-shows-ivonescimab-lung-cancer-mixed-results